

# PHARMACY UTILIZATION MANAGEMENT GUIDELINE – 5.01.560

## Excessively High Cost Drug Products with Lower Cost Alternatives

Effective Date: Mar. 1, 2026  
Last Revised: Feb. 10, 2026  
Replaces: N/A

RELATED MEDICAL POLICIES:  
10.01.511 Medical Policy and Clinical Guidelines: Definitions and Procedures

Select a hyperlink below to be directed to that section.

[POLICY CRITERIA](#) | [DOCUMENTATION REQUIREMENTS](#) | [CODING](#)  
[RELATED INFORMATION](#) | [REFERENCES](#) | [HISTORY](#)

 Clicking this icon returns you to the hyperlinks menu above.

---

## Introduction

Often, several very similar drugs are available to treat the same condition. In some cases, a drug will be very expensive, while much lower cost drugs that are appropriate therapeutic alternatives may be prescribed instead and will work just as well. This policy defines the criteria that must be met and the drugs that must be tried first before specific excessively high cost drugs can be approved.

**Note:** The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

---

The drug products listed in this medical policy will be reviewed on a case-by-case basis and are subject to the criteria outlined **below**. These products are excessively high priced and have much lower cost alternatives that are equally safe and effective. Suggested alternatives are listed in the table below.

**Note: Documentation in the form of chart notes is required with every prior authorization request for the drugs listed in this policy.**

High Cost Drug Product	Suggested Alternatives
<b>Absorica (isotretinoin), Absorica LD (isotretinoin)</b>	Trial and failure of two of the following medications: Claravis, Zenatane, or Myorisan
<b>Alcortin-A</b>	Generic prescription topical corticosteroids
<b>Allzital</b>	Bultalbitol with acetaminophen (generics)
<b>Amrix (cyclobenzaprine extended-release) Cyclobenzaprine extended-release</b>	Generic cyclobenzaprine AND generic tizanidine or generic methocarbamol
<b>Auvi-Q</b>	Epinephrine Auto-Injector (generic EpiPen and generic Adrenaclick)
<b>Brand name EpiPen</b>	EpiPen Authorized Generic, Adrenaclick Authorized Generic
<b>Lorzone (chlorzoxazone) Chlorzoxazone 250 mg, 375 mg and 750 mg</b>	Generic chlorzoxazone 500 mg
<b>Pennsaid</b>	Generic topical diclofenac gel 1% AND generic topical diclofenac solution 1.5%
<b>Bethkis, Kitabis, TOBI</b>	Generic tobramycin solution
<b>Tobi Podhaler</b>	Generic tobramycin solution, Bethkis, Kitabis
<b>Fluoxetine</b>	Three tablets or capsules of generic fluoxetine 20mg.
<b>Fortamet Generic for Fortamet Glumetza Generic for Glumetza</b>	Generic metformin extended-release (generic for Glucophage XR)
<b>Metformin 625 mg (brand) Metformin 750 mg (brand)</b>	Generic metformin immediate-release
<b>Jublia Kerydin</b>	Generic ciclopirox AND generic tavaborole AND either generic terbinafine OR generic itraconazole
<b>Tavaborole</b>	Generic ciclopirox AND either generic terbinafine OR generic itraconazole
<b>Mytesi</b>	Trial and failure of two of the following medications: bismuth subsalicylate, diphenoxylate/atropine, or loperamide
<b>Northera</b>	Generic midodrine
<b>Kits</b>	Non-kit version of the active ingredients found within the kit. (such as: Livixil (lidocaine 2.5%/prilocaine 2.5% cream), Dermacinrx Silapak (triamcinolone acetonide cream 0.1% +dimethicone cream) etc.)



High Cost Drug Product	Suggested Alternatives
<b>Topical lidocaine products:</b> Ldo Plus L.E.T. Lidocaine HCl Lidocaine-Tetracaine Lidopin Lidotrex Lidozion Nynutey Pliaglis Vexasyn	Generic lidocaine HCL cream and generic lidocaine ointment
<b>Lidoderm Patches</b> <b>ZTlido</b>	Generic lidocaine patch, AND generic lidocaine HCL cream, AND generic lidocaine ointment
<b>Paingo KFT</b>	Generic lidocaine/prilocaine cream, AND generic lidocaine HCL cream, AND generic lidocaine ointment
<b>Rayos</b>	Generic prednisone AND generic methylprednisolone
<b>Riomet</b>	Generic metformin tablet
<b>Zyflo CR &amp; Zileuton ER, Zyflo &amp; Zileuton</b>	Generic montelukast

## Policy Coverage Criteria

Drug	Medical Necessity
<b>Absorica (isotretinoin), Absorica LD (isotretinoin)</b>	<p><b>Brand Absorica and Absorica LD may be considered medically necessary when the provider submits documentation in the form of medical records to show the following:</b></p> <ul style="list-style-type: none"> <li>The individual is aged 12 years or older</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>Has severe, recalcitrant, nodular acne</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>Has a documented trial of at least 3 months, and had an inadequate response or intolerance to 2 of the following generic medications: Amnesteem, Claravis, Isotretinoin, Myorisan or Zenatane</li> </ul>



Drug	Medical Necessity
<b>Alcortin-A (iodoquinol, hydrocortisone, Aloe polysaccharides)</b>	<p><b>Alcortin-A may be considered medically necessary when provider submits documentation in the form of medical records to show:</b></p> <ul style="list-style-type: none"> <li>The individual had an adequate trial, and had an inadequate response or intolerance to 2 generic prescription topical corticosteroids</li> </ul>
<b>Allzital (butalbital/acetaminophen)</b>	<p><b>Allzital may be considered medically necessary when:</b></p> <ul style="list-style-type: none"> <li>The individual is aged 16 years or older</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>Has documented trial of and had an inadequate response or intolerance to at least 2 generic butalbital/acetaminophen products</li> </ul>
<b>Amrix (cyclobenzaprine extended-release) Cyclobenzaprine extended-release</b>	<p><b>Brand Amrix and generic cyclobenzaprine extended-release may be considered medically necessary when provider submits documentation in the form of medical records to show:</b></p> <ul style="list-style-type: none"> <li>The individual had an adequate trial of at least 3 months, and had an inadequate response or intolerance to generic cyclobenzaprine</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>Had an adequate trial of at least 3 months, and had an inadequate response or intolerance of an additional muscle relaxant: tizanidine or methocarbamol</li> </ul>
<b>Auvi-Q (epinephrine injection)</b>	<p><b>Auvi-Q 0.15 mg/0.15 mL and Auvi-Q 0.3 mg/0.3 mL may be considered medically necessary when 1 of the following is true:</b></p> <ul style="list-style-type: none"> <li>The individual or caregiver lacks the manual dexterity or visual acuity needed to use Epinephrine Auto-Injector (generic Epipen and generic Adrenaclick)</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>The individual or caregiver lacks the mental capacity to be trained on how to use Epinephrine Auto-Injector (generic Epipen and generic Adrenaclick)</li> </ul> <p><b>Auvi-Q 0.1 mg/0.1 mL may be considered medically necessary when the following criteria are met:</b></p>



Drug	Medical Necessity
	<ul style="list-style-type: none"> <li>The individual's body weight is between 16.5 to 33 pounds (7.5 to 15 kilograms)</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>The caregiver lacks the manual dexterity or visual acuity needed to use Epinephrine Auto-Injector (generic Epipen and generic Adrenaclick)</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>The caregiver lacks the mental capacity to be trained on how to use Epinephrine Auto-Injector (generic Epipen and generic Adrenaclick)</li> </ul>
<p><b>Bethkis (tobramycin inhalation solution), Kitabis Pak (tobramycin inhalation solution), TOBI (tobramycin inhalation solution), TOBI Podhaler (tobramycin inhalation powder)</b></p>	<p><b>Bethkis (tobramycin inhalation solution), Kitabis Pak (tobramycin inhalation solution) and TOBI (tobramycin inhalation solution) may be considered medically necessary for the management of cystic fibrosis when:</b></p> <ul style="list-style-type: none"> <li>The individual has tried generic tobramycin inhalation solution and had an inadequate response after 1-month of treatment or had intolerance to generic tobramycin inhalation solution</li> </ul> <p><b>TOBI Podhaler (tobramycin inhalation powder) may be considered medically necessary for the management of cystic fibrosis when:</b></p> <ul style="list-style-type: none"> <li>The individual has tried generic tobramycin inhalation solution and had an inadequate response after 1-month of treatment or had intolerance to generic tobramycin inhalation solution</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>Has tried Bethkis (tobramycin inhalation solution) or Kitabis Pak (tobramycin inhalation solution)</li> </ul> <p><b>Initial therapy may be approved up to 3 years.</b></p> <p><b>Reauthorization criteria:</b></p> <ul style="list-style-type: none"> <li>Continued therapy may be approved up to 3 years as long as the medical necessity criteria are met and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.</li> </ul>



Drug	Medical Necessity
<p><b>Generic chlorzoxazone, Lorzone (chlorzoxazone)</b></p>	<p><b>Generic chlorzoxazone 250 mg or 750 mg tablets and brand Lorzone 750 mg tablets may be considered medically necessary when:</b></p> <ul style="list-style-type: none"> <li>• Provider submits documentation that the individual has tried and did not tolerate chlorzoxazone 500 mg tablets or achieve therapeutic response with chlorzoxazone 500 mg tablets</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Individual or caregiver lacks the manual dexterity or visual acuity needed to cut chlorzoxazone 500 mg tablets</li> </ul> <p><b>Generic chlorzoxazone 375 mg tablets and brand Lorzone 375 mg tablets may be considered medically necessary when:</b></p> <ul style="list-style-type: none"> <li>• Provider submits documentation that the individual has tried and did not tolerate chlorzoxazone 500 mg tablets</li> </ul> <p><b>Note:</b> Chlorzoxazone 500 mg tablets are scored and can be cut in half to deliver a 250 mg dose or a 750 mg dose.</p>
<p><b>Generic droxidopa</b></p>	<p><b>Generic droxidopa may be considered medically necessary when all the following criteria are met:</b></p> <ul style="list-style-type: none"> <li>• The individual is aged 18 years or older</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Diagnosed with symptomatic neurogenic orthostatic hypotension</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Has tried and had an inadequate response or intolerance to non-pharmacologic therapy (e.g., adjusting salt intake, drinking adequate water, avoiding alcohol, reducing meal size, elevating the head of bed, use of compression stockings)</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Has tried and had an inadequate response or intolerance to 1 month of therapy with the maximum tolerated dose of midodrine unless there is a contraindication to use of midodrine</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Medication is prescribed by or in consultation with a neurologist or cardiologist</li> </ul>



Drug	Medical Necessity
	<p><b>Initial therapy may be approved up to 1 month.</b></p> <p><b>Reauthorization criteria:</b></p> <ul style="list-style-type: none"> <li>Continued therapy may be approved up to 12 months when documented evidence shows the individual experienced improvement in symptoms for neurogenic orthostatic hypotension.</li> </ul>
<p><b>Brand EpiPen (epinephrine injection)</b></p>	<p><b>Brand EpiPen (epinephrine injection) may be considered medically necessary when provider submits documentation in the form of medical records to explain why individual is not a candidate for the use of the following preferred options:</b></p> <ul style="list-style-type: none"> <li>Generic epinephrine auto-injector</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>EpiPen authorized generic*</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>Adrenacllick authorized generic*</li> </ul> <p><b>Note:</b> *An authorized generic is defined by the Food and Drug Administration as: "The term "authorized generic" drug is most commonly used to describe an approved, brand name drug that is marketed as a generic product without the brand name on its label. Other than the fact that it does not have the brand name on its label, it is the exact same drug product as the branded product. It may be marketed by the brand name drug company, or another company with the brand company's permission. In some cases, even though it is the same as the brand name product, the authorized generic may be sold at a lower cost than the brand name drug."</p>
<p><b>Fluoxetine 60mg tablets</b></p>	<p><b>Fluoxetine 60mg tablets may be considered medically necessary when BOTH of the following criteria are met:</b></p> <ul style="list-style-type: none"> <li>The individual has 1 of the following conditions, as documented by the chart notes: <ul style="list-style-type: none"> <li>Major Depressive Disorder (MDD)* in individuals aged 8 years or older</li> <li>Obsessive Compulsive Disorder (OCD)* in individuals aged 7 years or older</li> <li>Bulimia Nervosa in individual aged 18 years or older</li> </ul> </li> </ul>



Drug	Medical Necessity
	<ul style="list-style-type: none"> <li>○ Panic Disorder with or without agoraphobia in individuals aged 18 years or older</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>● Is non-adherent** on therapy with 3 tablets or capsules of generic fluoxetine 20mg, as documented by the chart notes</li> </ul> <p><b>Note:</b> *Fluoxetine 60mg is FDA-approved for use in pediatric individuals only for MDD and OCD. The safety and efficacy in those less than 8 and less than 7 years of age, respectively has not been established.</p> <p><b>Note:</b> **Non-adherence is defined as less than 50% adherence over a 6-months period.</p>
<p><b>Fortamet, Glumetza (metformin extended release), and their generic</b></p>	<p><b>Fortamet and Glumetza, as well as the generic version of these medications, may be considered medically necessary when all the following criteria are met:</b></p> <ul style="list-style-type: none"> <li>● The individual has tried and had an inadequate response or intolerance to generic metformin immediate release</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>● Has tried and had an inadequate response or intolerance to generic metformin extended release (generic for Glucophage XR): <ul style="list-style-type: none"> <li>○ In an event such that individual experiences intolerance to a generic metformin extended release (generic for Glucophage XR), documentation of the attempts to minimize the adverse effects where appropriate is necessary to qualify for Glumetza and/or its generic version.</li> <li>○ Dose de-escalation, in addition to taking the drug with meals before attempting a re-challenge of the preferred agent, metformin extended release (generic for Glucophage XR) are required to establish and confirm intolerance to the preferred agent. <ul style="list-style-type: none"> <li>▪ Metformin extended release should be started at a low dose with gradual dose escalation over 4 to 8 weeks</li> <li>▪ Re-challenge period should last at a minimum of at least 3 months</li> </ul> </li> </ul> </li> </ul>



Drug	Medical Necessity
<b>Jublia (efinaconazole), Kerydin (tavaborole) (topical antifungal agents)</b>	<p><b>Jublia (efinaconazole) and Kerydin (tavaborole) may be considered medically necessary when:</b></p> <ul style="list-style-type: none"> <li>• The individual has a documented diagnosis of onychomycosis confirmed by a positive KOH (potassium hydroxide) test AND a fungal culture <ul style="list-style-type: none"> <li>○ Copy of the KOH test and culture results are required</li> </ul> </li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Has a documented trial of at least 3 months of continuous therapy and had an inadequate response or intolerance of ALL the following: <ul style="list-style-type: none"> <li>○ Generic ciclopirox (topical)</li> </ul> </li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>○ Generic tavaborole (topical)</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>○ Generic terbinafine OR itraconazole, unless such are contraindicated or not tolerated</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Total duration of therapy is not to exceed 48 weeks</li> </ul>
<b>Kits</b>	<p><b>Excessively high cost kits (containing one or more drugs, often packaged with medical supplies such as sterile gloves) may be considered medically necessary when:</b></p> <ul style="list-style-type: none"> <li>• Individual has a documented trial for at least 3 months with ALL dosage forms of ALL active ingredients in the kit, and had inadequate response or intolerance on continuous use</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• There is a documented specific clinical rationale for the individual not being able to use each of the ingredients within the kit separately</li> </ul> <p><b>The use of excessively high cost kits solely for the convenience of either provider or individual is considered not medically necessary.</b></p>
<b>Topical lidocaine products</b> <ul style="list-style-type: none"> <li>• Ldo Plus</li> <li>• L.E.T.</li> <li>• Lidocaine HCl</li> <li>• Lidocaine-Tetracaine</li> </ul>	<p><b>Ldo Plus, L.E.T., Lidocaine HCl, Lidocaine-Tetracaine, Lidopin, Lidotrex, Lidozion, Nynutey, Pliaglis, and Vexasyn may be considered medically necessary when:</b></p>



Drug	Medical Necessity
<ul style="list-style-type: none"> <li>• Lidopin</li> <li>• Lidotrex</li> <li>• Lidozion</li> <li>• Nynutey</li> <li>• Pliaglis</li> <li>• Vexasyn</li> </ul>	<ul style="list-style-type: none"> <li>• The individual has a documented trial of at least 3 months of continuous therapy, and had an inadequate response or intolerance to ALL of the following:               <ul style="list-style-type: none"> <li>○ Generic lidocaine HCL cream</li> </ul> </li> <li><b>AND</b></li> <li>○ Generic lidocaine ointment</li> </ul>
<ul style="list-style-type: none"> <li>• Lidoderm Patches</li> <li>• ZTlido</li> </ul>	<p><b>Lidoderm patches and ZTlido may be considered medically necessary when:</b></p> <ul style="list-style-type: none"> <li>• Individual has a documented trial of at least 3 months of continuous therapy, and had an inadequate response or intolerance to ALL of the following:               <ul style="list-style-type: none"> <li>○ Generic lidocaine patch</li> </ul> </li> <li><b>AND</b></li> <li>○ Generic lidocaine HCL cream</li> <li><b>AND</b></li> <li>○ Generic lidocaine ointment</li> </ul>
<ul style="list-style-type: none"> <li>• Brand metformin 625 mg tablets</li> <li>• Brand metformin 750 mg tablets</li> </ul>	<p><b>Brand metformin 625 mg tablets and brand metformin 750 mg tablets may be considered medically necessary when all of the following criteria are met:</b></p> <ul style="list-style-type: none"> <li>• The individual is aged 10 years or older</li> <li><b>AND</b></li> <li>• Diagnosed with type 2 diabetes mellitus</li> <li><b>AND</b></li> <li>• Has a documented trial of at least 2 months of continuous therapy for each metformin product, and had an inadequate response or intolerance with 2 of the following generic metformin immediate-release products:               <ul style="list-style-type: none"> <li>○ Metformin 500 mg tablets</li> <li>○ Metformin 850 mg tablets</li> <li>○ Metformin 1,000 mg tablets</li> </ul> </li> <li><b>AND</b></li> <li>• The dose prescribed is limited to 2,500 mg per day</li> </ul>
<p><b>Mytesi (crofelemer)</b></p>	<p><b>Mytesi (crofelemer) may be considered medically necessary for the symptomatic relief of non-infectious diarrhea when all the following criteria are met:</b></p> <ul style="list-style-type: none"> <li>• The individual is aged 18 years or older</li> <li><b>AND</b></li> </ul>



Drug	Medical Necessity
	<ul style="list-style-type: none"> <li>• Diagnosed with HIV/AIDS and on anti-retroviral therapy</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Has a documented trial of at least 1 month of continuous therapy for each drug, and had an inadequate response or intolerance with 2 of the following:               <ul style="list-style-type: none"> <li>○ Bismuth subsalicylate</li> <li>○ Diphenoxylate/atropine</li> <li>○ Loperamide</li> </ul> </li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• The dose is limited to 250 mg per day (taken as 125 mg twice daily)</li> </ul>
<b>Northera (droxidopa)</b>	<p><b>Northera (droxidopa) may be considered medically necessary when all the following criteria are met:</b></p> <ul style="list-style-type: none"> <li>• The individual is aged 18 years or older</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Diagnosed with symptomatic neurogenic orthostatic hypotension</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Has tried and had an inadequate response or intolerance to non-pharmacologic therapy (e.g., adjusting salt intake, drinking adequate water, avoiding alcohol, reducing meal size, elevating the head of bed, use of compression stockings)</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Has tried and had an inadequate response or intolerance to 1 month of therapy with the maximum tolerated dose of midodrine unless there is a contraindication to use of midodrine</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Has tried and had an inadequate response or intolerance to generic droxidopa</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Northera is prescribed by or in consultation with a neurologist or cardiologist</li> </ul> <p><b>Initial therapy may be approved up to 1 month.</b></p> <p><b>Reauthorization criteria:</b></p>



Drug	Medical Necessity
	<ul style="list-style-type: none"> <li>Continued therapy may be approved up to 12 months when documented evidence shows the individual experienced improvement in symptoms for neurogenic orthostatic hypotension.</li> </ul>
<b>Paingo KFT</b>	<p><b>Paingo KFT may be considered medically necessary when:</b></p> <ul style="list-style-type: none"> <li>The individual has a documented trial of at least 3 months of continuous therapy, and had an inadequate response or intolerance to ALL of the following: <ul style="list-style-type: none"> <li>Generic lidocaine/prilocaine cream</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>Generic lidocaine HCL cream</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>Generic lidocaine ointment</li> </ul> </li> </ul>
<b>Pennsaid (diclofenac sodium topical solution)</b>	<p><b>Pennsaid (diclofenac sodium topical solution) may be considered medically necessary when:</b></p> <ul style="list-style-type: none"> <li>The individual has a documented diagnosis of osteoarthritis of the knee(s)</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>Has a documented trial of at least 3 months of continuous therapy, and had an inadequate response or intolerance to ALL of the following: <ul style="list-style-type: none"> <li>Generic diclofenac topical gel 1%</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>Generic topical diclofenac solution 1.5%</li> </ul> </li> </ul>
<b>Rayos (prednisone delayed-release)</b>	<p><b>Rayos may be considered medically necessary when:</b></p> <ul style="list-style-type: none"> <li>Individual has a documented trial of at least 3 months of continuous therapy, and had an inadequate response or intolerance to ALL of the following: <ul style="list-style-type: none"> <li>Generic prednisone</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>Methylprednisolone</li> </ul> </li> </ul>
<b>Riomet (metformin oral solution)</b>	<p><b>Riomet (metformin) may be considered medically necessary when 1 of the following documented reasons is provided as to why the oral tablet of the generically available metformin is not appropriate for the individual:</b></p>



Drug	Medical Necessity
	<ul style="list-style-type: none"> <li>The individual is unable to swallow tablets</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>Has compromised ability to absorb tablets</li> </ul>
<p><b>Generic tavaborole (topical antifungal solution)</b></p>	<p><b>Generic tavaborole (topical) may be considered medically necessary when:</b></p> <ul style="list-style-type: none"> <li>The individual has a documented diagnosis of onychomycosis confirmed by a positive KOH (potassium hydroxide) test AND a fungal culture <ul style="list-style-type: none"> <li>Copy of the KOH test and culture results are required</li> </ul> </li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>Has a documented trial of at least 3 months of continuous therapy, and had an inadequate response or intolerance to ALL of the following: <ul style="list-style-type: none"> <li>Generic ciclopirox (topical)</li> </ul> </li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>Generic terbinafine OR itraconazole, unless such are contraindicated or not tolerated</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>Total duration of therapy is not to exceed 48 weeks</li> </ul>
<p><b>Zileuton, Zileuton extended-release Zyflo (zileuton)</b></p>	<p><b>Zileuton, zileuton extended-release, or Zyflo (zileuton) may be considered medically necessary when provider submits documentation in the form of medical records to show:</b></p> <ul style="list-style-type: none"> <li>The individual had an adequate trial of at least 3 months, and had an inadequate response or intolerance to generic montelukast</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>The quantity is limited to 120 tablets per 30 days</li> </ul>

Drug	Not Medically Necessary
<p><b>As listed</b></p>	<p><b>All other uses of the drugs listed in this policy are considered not medically necessary.</b></p>



Drug	Investigational
As listed	The medications listed in this policy are subject to the product's US Food and Drug Administration (FDA) dosage and administration prescribing information.

Length of Approval	
Approval	Criteria
Initial authorization	<p>Non-formulary exception reviews for all drugs listed in this policy may be approved up to 12 months.</p> <p>For all other reviews unless noted otherwise for specific drugs under the medical necessity criteria the drugs listed in policy may be approved up to 12 months.</p>
Re-authorization criteria	<p>Non-formulary exception reviews for all drugs listed in this policy may be approved up to 12 months as long as the drug-specific coverage criteria are met, and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.</p> <p>For all other reviews unless noted otherwise for specific drugs under the medical necessity criteria future re-authorization of the drugs listed may be approved up to 12 months as long as the medical necessity criteria are met, and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.</p>

Documentation Requirements
<p>The individual's medical records submitted for review for all conditions should document that medical necessity criteria are met. The record should include the following:</p> <ul style="list-style-type: none"> <li>Office visit notes that contain the diagnosis, relevant history, physical evaluation and medication history</li> </ul>

## Coding



N/A

## Related Information

### Definition of Medical Necessity

Those covered services and supplies that a physician, exercising prudent clinical judgment, would provide to an individual for the purpose of preventing, evaluating, diagnosing, or treating an illness, injury, disease or its symptoms, and that are:

1. In accordance with generally accepted standards of medical practice; and
2. Clinically appropriate, in terms of type, frequency, extent, site and duration, and considered effective for the individual's illness, injury or disease; and
3. Not primarily for the convenience of the individual, physician, or other health care provider, and
4. Not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that individual's illness, injury or disease.

For these purposes, "generally accepted standards of medical practice" means standards that are based on reliable scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, physician specialty society recommendations, and the views of physicians practicing in relevant clinical areas and any other relevant factors.

A recent disturbing trend threatens to drive substantial increases in pharmaceutical expenditures. Opportunistic pharmaceutical companies are buying up products and raising the prices by 500% or more overnight. In addition, these companies are marketing kits, which combine a prescription medication with a medical supply or OTC products. These kits far exceed the cost of each individual product alone. These companies do not do research to originate new products and add no value to what they purchase. Unfortunately, some of these products are one of a kind, and thus have a captive audience. Recent media attention has been drawn to Daraprim (pyrimethamine), an antiprotozoal drug for which there are no comparable alternatives that was purchased by Turing Pharmaceuticals (now Vyera Pharmaceuticals), who raised the price overnight from \$13.50 per tablet to \$750.



## Definition of Kit

Kits are defined as a combination of a prescription medication with a medical supply or OTC product, in which the combination of these products far exceeds the cost of each individual product.

## Consideration of Age

The ages noted in the policy statements are based on the FDA labeling for these agents.

## 2019 Update

Reviewed prescribing information and updated drug lists documented for each therapeutic class. No new evidence was identified that require changes to existing criteria.

## 2020 Update

Reviewed prescribing information and added Absorica LD to policy with same criteria as Absorica. Updated criteria for Alcantin-A to require trial of two generic prescription topical corticosteroids first.

## 2021 Update

Reviewed prescribing information and generic availability for drugs referenced in policy. Updated brand name EpiPen (epinephrine injection) and Adrenaclick (epinephrine injection) to include generic epinephrine auto-injector as one of the preferred options prior to brand EpiPen or Adrenaclick.



## 2022 Update

Reviewed product availability for all drugs referenced in policy. Removed Vanatol LQ (butalbital/acetaminophen) and Vanatol S (butalbital/acetaminophen) from policy as products are no longer available. Removed from topical lidocaine products Reciphexamine, Silvera, and Velma as products are no longer available

## 2023 Update

Reviewed product availability for all drugs referenced in policy. Removed from topical lidocaine products eLenzaPatch, Lidodextrapine, Relyyks, and lidocaine-epinephrine-tetracaine as products are no longer available.

## 2024 Update

Reviewed product availability for all drugs referenced in policy. Removed Adrenaclick (epinephrine injection), Evzio (naloxone), and Zyflo CR (zileuton extended-release) from the policy as these products are no longer available.

## 2025 Update

Reviewed product availability for all drugs referenced in policy. Removed Natpara (parathyroid hormone) from the policy as it has been withdrawn from the market. Added brand metformin 750 mg to the brand metformin criteria. Clarified that non-formulary exception review authorizations for all drugs listed in this policy may be approved up to 12 months. Clarified that the medications listed in this policy are subject to the product's FDA dosage and administration prescribing information. Removed Riomet ER (metformin) from the policy as it has been withdrawn from the market.

## 2026 Update

Reviewed product availability for all drugs referenced in policy. Removed coverage criteria for Adazin, Lidocaine 3.88%, Pain Relief, Regenecare, Scar, and Synvexia TC. Removed coverage criteria for Synera patches and Sitavig as they have been withdrawn from the market. Updated



coverage criteria for zileuton extended-release and Zylfo adding a quantity limit of 120 tablets per 30 days. Added coverage criteria for generic droxidopa for adult individuals with symptomatic neurogenic orthostatic hypotension (nOH). Updated coverage criteria of Northera (droxidopa) to require trial of generic droxidopa.

## References

1. Luo J, Sarpatwari A, Kesselheim AS. Regulatory Solutions to the Problem of High Generic Drug Costs. Open Forum Infect Dis. 2015 Dec; 2(4): ofv179.
2. Gallant J. Get Rich Quick With Old Generic Drugs! The Pyrimethamine Pricing Scandal. Open Forum Infect Dis. 2015 Dec; 2(4): ofv177.
3. Rockoff JD, Silverman E. Pharmaceutical Companies Buy Rivals' Drugs, Then Jack Up the Prices. Wall Street Journal April 26, 2015. Available at <http://www.wsj.com/articles/pharmaceutical-companies-buy-rivals-drugs-then-jack-up-the-prices-1430096431> Accessed January 27, 2026.
4. Stiglitz JE. Don't Trade Away Our Health. New York Times. January 30, 2015. Available at [http://www.nytimes.com/2015/01/31/opinion/dont-trade-away-our-health.html?\\_r=0](http://www.nytimes.com/2015/01/31/opinion/dont-trade-away-our-health.html?_r=0) Accessed January 27, 2026.
5. Martin AB, Hartman M, Benson J, et al. National Health Spending In 2014: Faster Growth Driven By Coverage Expansion And Prescription Drug Spending. Health Affairs 2016 35:150-160.
6. Pollack A, Tavernise S. Valeant's Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers. New York Times October 4, 2015. Available at [http://www.nytimes.com/2015/10/05/business/valeants-drug-price-strategy-enriches-it-but-infuriates-patients-and-lawmakers.html?\\_r=0](http://www.nytimes.com/2015/10/05/business/valeants-drug-price-strategy-enriches-it-but-infuriates-patients-and-lawmakers.html?_r=0) Accessed January 27, 2026.

## History

Date	Comments
02/09/16	New Utilization Management Guideline, add to Prescription Drug section. Excessively high cost drug products with lower cost alternatives are considered not medically necessary for all indications.
05/01/16	Annual Review, approved April 12, 2016. Addition of a new agent, Evzio, and its criteria to the policy. Revision of the criteria for Glumetza and its generic agent.
11/01/16	Interim Review, approved October 11, 2016. Inclusion of new agents and their associated criteria to the policy: DermacinRx Lexitral PharmaPak, Diclotral Pak, Pennsaid, Xrylix, Rayos, Jublia, Kerydin, and Zegerid.
12/01/16	Interim Review, approved November 8, 2016. Adding Zegerid's generic to the edit.



Date	Comments
01/01/17	Interim Review, approved December 13, 2016. Criteria for fluoxetine 60mg tablets has been added to the policy.
01/26/17	Interim Update. Added Auvi-Q and its related criteria.
02/01/17	Annual Review, approved January 10, 2017. Added Xelitral, Sure Result DSS Premium Pack, and Diclo Gel with Xrylix Sheets 1% kit to the topical NSAIDs criteria.
03/01/17	Interim Review, approved February 14, 2017. Addition of brand name EpiPen, Adrenacllick, Fortamet, and its generic, Riomet, and Alcortin-A.
04/01/17	Interim Review, approved March 14, 2017. Addition of brand drug Differin and its generic version adapalene.
08/01/17	Interim Review, Approved July 25, 2017. Addition of excessively high cost kits.
09/01/17	Interim Review, approved August 22, 2017. Addition of Amrix ER, omeprazole ODT, and Zyflo CR/Zileuton ER & Zyflo/Zileuton. Addition of Absorica and new criteria for Differin.
10/01/17	Interim Review, approved September 21, 2017. Changed criteria for Differin, clarified criteria for auvi-q, added criteria for omePPI.
01/01/18	Interim Review, approved December 20, 2017. Updated drugs targeted by topical NSAIDs edit.
03/01/18	Annual Review, approved February 27, 2018. Addition of various topical lidocaine products to policy as well as criteria for these products.
07/01/18	Interim Review, approved June 5, 2018. Addition of various topical lidocaine products and generic Alcortin-A to existing criteria. Generic Daraprim name was corrected.
09/12/18	Interim Review, approved September 11, 2018. Added Consideration of Age information. Added Vexasyn, removed Differin/Adapalene criteria from this policy as it was moved to policy 5.01.605.
11/01/18	Interim Review, approved October 26, 2018. Added Allzital, Vanatol LQ, Vanatol S, and multiple topical lidocaine products.
02/01/19	Interim Review, approved January 4, 2019. Added Suvicort as topical lidocaine product.
03/01/19	Interim Review, approved February 25, 2019. Updated Absorica criteria. Updated Glumetza, Fortamet and their generic criteria.
05/01/19	Annual Review, approved April 9, 2019. Added ZTlido to policy and generic cyclobenzaprine extended-release. Added criteria for Natpara (parathyroid hormone) to policy. Added Auvi-Q 0.1 mg/0.1 mL criteria.
06/01/19	Interim Review, approved May 23, 2019. Added L.E.T. as topical lidocaine product. Added criteria for Lorzone and generic chlorzoxazone to policy.



Date	Comments
08/01/19	Interim Review, approved July 9, 2019. Added criteria for the deferasirox products Exjade, Jadenu and Jadenu Sprinkle. Added criteria for the tobramycin inhaled products Bethkis, Kitabis Pak, TOBI and TOBI Podhaler.
10/01/19	Interim Review, approved September 19, 2019. Moved the deferasirox products Exjade, Jadenu and Jadenu Sprinkle to policy 5.01.613 Oral Iron Chelating Agents.
03/01/20	Annual Review, approved February 20, 2020. Added Absorica LD to policy with same criteria as Absorica. Updated criteria for Alcantin-A.
04/01/20	Interim Review, approved March 10, 2020. Added criteria for Northera (droxidopa) for treatment of symptomatic neurogenic orthostatic hypotension. Added Riomet ER to policy with same criteria as Riomet.
07/01/20	Interim Review, approved June 9, 2020. Added criteria for Sitavig (acyclovir buccal tablets) for the treatment of cold sores.
09/01/20	Interim Review, approved August 11, 2020. Changed lidocaine lotion to lidocaine ointment as part of requirement for coverage criteria for all Topical Lidocaine Products and Lidoderm, Synera, ZTlido, and Paingo KFT. Change made due to lidocaine lotion being no longer available. Added criteria for Mytesi (crofelemer) for the treatment of non-infectious diarrhea.
11/01/20	Interim Review, approved October 22, 2020. Moved omeprazole ODT, Zegerid (omeprazole/sodium bicarbonate), and generic omeprazole/sodium bicarbonate to Policy 5.01.605 Medical Necessity Criteria for Pharmacy Edits.
02/01/21	Interim Review, approved January 12, 2021. Added step therapy for generic tavorole to Jublia and Kerydin criteria. Added new criteria for generic tavorole. Removed from topical lidocaine products Anastia, Astero, Kamdoy, Lido-K, Lidorx, Lidotral, Lidovex, Lidtopic Max, Numbonex, Suvicort, Tranzarel, and Vexasyn as these drugs are not approved by the FDA and have coverage blocked under pharmacy benefit.
11/01/21	Annual Review, approved October 5, 2021. Updated brand name EpiPen (epinephrine injection) and Adrenaclik (epinephrine injection) to include generic epinephrine auto-injector as one of the preferred options.
06/01/22	Annual Review, approved May 9, 2022. Removed Vanatol LQ (butalbital/acetaminophen) and Vanatol S (butalbital/acetaminophen) from policy as products are no longer available. Removed from topical lidocaine products Reciphexamine, Silvera, and Velma as products are no longer available.
10/01/22	Interim Review, approved September 13, 2022. Added criteria for brand metformin 625 mg tablets. Changed the wording from "patient" to "individual" throughout the policy for standardization.
08/01/23	Annual Review, approved July 10, 2023. Added Nynutey to the topical lidocaine products. Removed from topical lidocaine products eLenzaPatch, Lidodextrapine, Relyyks, and lidocaine-epinephrine-tetracaine as products are no longer available.



Date	Comments
07/01/24	Annual Review, approved June 24, 2024. Removed Adrenaclick (epinephrine injection), Evzio (naloxone), and Zyflo CR (zileuton extended-release) from the policy as these products are no longer available.
07/01/25	Annual Review, approved June 9, 2025. Removed Natpara (parathyroid hormone) from the policy as it has been withdrawn from the market. Added brand metformin 750 mg to the brand metformin criteria. Clarified that non-formulary exception review authorizations for all drugs listed in this policy may be approved up to 12 months. Clarified that the medications listed in this policy are subject to the product's FDA dosage and administration prescribing information.
11/01/25	Interim Review, approved October 27, 2025. Removed Riomet ER (metformin) from the policy as it has been withdrawn from the market.
03/01/26	Annual Review, approved February 10, 2026. Removed coverage criteria for Adazin, Lidocaine 3.88%, Pain Relief, Regenecare, Scar, and Synvexia TC. Removed coverage criteria for Synera patches and Sitavig as they have been withdrawn from the market. Updated coverage criteria for zileuton extended-release and Zyflo adding a quantity limit of 120 tablets per 30 days. Added coverage criteria for generic droxidopa for adult individuals with symptomatic neurogenic orthostatic hypotension (nOH). Updated coverage criteria of Northera (droxidopa) to require trial of generic droxidopa.

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2026 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.

